Arcus Biosciences, Inc. (NYSE:RCUS - Get Free Report) shares shot up 8.1% during trading on Wednesday . The stock traded as high as $9.07 and last traded at $9.19. 192,520 shares changed hands during mid-day trading, a decline of 78% from the average session volume of 880,360 shares. The stock had previously closed at $8.50.
Wall Street Analysts Forecast Growth
Several brokerages have commented on RCUS. Morgan Stanley dropped their target price on shares of Arcus Biosciences from $24.00 to $22.00 and set an "overweight" rating for the company in a research report on Friday, May 9th. The Goldman Sachs Group lowered their price objective on shares of Arcus Biosciences from $15.00 to $13.00 and set a "neutral" rating for the company in a research report on Thursday, May 8th. Wells Fargo & Company lowered their price objective on shares of Arcus Biosciences from $29.00 to $26.00 and set an "overweight" rating for the company in a research report on Wednesday, May 7th. Wedbush restated an "outperform" rating and issued a $33.00 price objective on shares of Arcus Biosciences in a research report on Wednesday, May 7th. Finally, Barclays lowered their price objective on shares of Arcus Biosciences from $29.00 to $14.00 and set an "overweight" rating for the company in a research report on Wednesday, April 23rd. Two analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $21.29.
View Our Latest Analysis on RCUS
Arcus Biosciences Stock Performance
The stock has a fifty day simple moving average of $8.87 and a two-hundred day simple moving average of $10.24. The stock has a market cap of $1.01 billion, a price-to-earnings ratio of -2.27 and a beta of 0.80. The company has a debt-to-equity ratio of 0.09, a quick ratio of 5.37 and a current ratio of 5.37.
Arcus Biosciences (NYSE:RCUS - Get Free Report) last issued its earnings results on Tuesday, May 6th. The company reported ($1.14) earnings per share for the quarter, missing analysts' consensus estimates of ($1.02) by ($0.12). Arcus Biosciences had a negative net margin of 258.94% and a negative return on equity of 70.58%. The business had revenue of $28.00 million during the quarter, compared to analyst estimates of $38.61 million. During the same period in the prior year, the business posted ($0.05) EPS. The company's revenue for the quarter was down 80.7% compared to the same quarter last year. Analysts expect that Arcus Biosciences, Inc. will post -3.15 EPS for the current fiscal year.
Hedge Funds Weigh In On Arcus Biosciences
A number of hedge funds have recently made changes to their positions in the stock. Bank of New York Mellon Corp grew its holdings in Arcus Biosciences by 8.6% during the 4th quarter. Bank of New York Mellon Corp now owns 381,615 shares of the company's stock worth $5,682,000 after acquiring an additional 30,290 shares during the period. US Bancorp DE boosted its position in shares of Arcus Biosciences by 2,432.0% during the 4th quarter. US Bancorp DE now owns 6,887 shares of the company's stock valued at $103,000 after purchasing an additional 6,615 shares in the last quarter. Charles Schwab Investment Management Inc. grew its stake in Arcus Biosciences by 2.2% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 579,623 shares of the company's stock worth $8,631,000 after purchasing an additional 12,644 shares during the period. Raymond James Financial Inc. bought a new stake in Arcus Biosciences in the fourth quarter worth approximately $531,000. Finally, Amundi increased its holdings in Arcus Biosciences by 137.0% in the fourth quarter. Amundi now owns 27,030 shares of the company's stock worth $403,000 after purchasing an additional 15,624 shares in the last quarter. 92.89% of the stock is currently owned by institutional investors.
About Arcus Biosciences
(
Get Free Report)
Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.
Featured Articles
Before you consider Arcus Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Arcus Biosciences wasn't on the list.
While Arcus Biosciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
